Pawan Rao, MD
Nephrology · North Syracuse, NYNPI 1730283144
Payments from drug & device makers
Across 213 payments — averaging $52.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$7K
- Amgen$594
- AstraZeneca$399
- Vifor Pharma, Inc.$388
- Otsuka America Pharmaceutical, Inc.$371
- GSK$280
- plus $2K from 23 others
What the payments were for
- Consulting fees$5,20046%
- Travel & lodging$1,36612%
- Food & beverage$4,26338%
- Education$3633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 20 | $7,126 |
| Amgen(2 entities) | 35 | $594 |
| AstraZeneca | 14 | $399 |
| Vifor Pharma, Inc. | 16 | $388 |
| Otsuka America Pharmaceutical, Inc. | 12 | $371 |
| GSK | 18 | $280 |
| Aurinia Pharma U.S., Inc. | 9 | $269 |
| Fresenius USA Marketing, Inc. | 13 | $223 |
| Bayer | 10 | $216 |
| OPKO Pharmaceuticals, LLC | 9 | $196 |
| Novartis | 7 | $166 |
| ANI Pharmaceuticals, Inc. | 11 | $148 |
| Novo Nordisk | 8 | $127 |
| Calliditas Therapeutics US Inc. | 5 | $95 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $90 |
| Ardelyx, Inc. | 3 | $85 |
| Abbott | 3 | $71 |
| Akcea Therapeutics, Inc. | 1 | $54 |
| Amarin Pharma, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $44 |
| Baxter Healthcare | 2 | $42 |
| Akebia Therapeutics Inc | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Genentech USA, Inc. | 1 | $19 |
| Merck | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,193 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 19 | $280,293 |
| FarxigaDapagliflozin Propanediol | 245 | $258,926 |
| JardianceEmpagliflozin | 220 | $242,337 |
| VelphoroSucroferric Oxyhydroxide | 54 | $174,125 |
| OzempicSemaglutide | 114 | $132,099 |
| RetacritEpoetin Alfa-Epbx | 41 | $79,941 |
| KerendiaFinerenone | 68 | $76,502 |
| EliquisApixaban | 40 | $59,568 |
| MounjaroTirzepatide | 48 | $58,961 |
| BenlystaBelimumab | 12 | $57,176 |
| TrulicityDulaglutide | 36 | $56,846 |
| JanuviaSitagliptin Phosphate | 47 | $53,749 |
| ProcritEpoetin Alfa | 11 | $44,357 |
| AuryxiaFerric Citrate | 20 | $37,580 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $31,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $371 | $280,29319 claims |
| AstraZenecaFarxiga, Lokelma | $399 | $278,073265 claims |
| Boehringer IngelheimJardiance | $44 | $242,337220 claims |
| Fresenius USA Marketing, Inc.Velphoro | $223 | $174,12554 claims |
| Novo NordiskOzempic | $127 | $132,099114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $14 | $115,80784 claims |
| BayerKerendia | $216 | $76,50268 claims |
| GSKBenlysta | $280 | $57,17612 claims |
| MerckJanuvia | $14 | $53,74947 claims |
| Johnson & JohnsonProcrit | $12 | $44,35711 claims |
| Akebia Therapeutics IncAuryxia | $37 | $37,58020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in North Syracuse
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.